Skip to search formSkip to main contentSkip to account menu

3'-deamino-3'-hydroxydoxorubicin

Known as: 3-DHD, 5,12-Naphthacenedione, 10-((2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, hydroxyrubicin 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

EpirubicinTopoisomerase II Inhibitors
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma
Objective: This phase Ia study was designed to assess the pharmacokinetic (PK) characters of free vincristine (F-VCR, refer to as… 
2007
2007
N-Benzyladriamycin-14-valerate (AD 198): A Non-Cardiotoxic Anthracycline That Is Cardioprotective through PKC-ϵ Activation
N-Benzyladriamycin-14-valerate (AD 198) is one of several novel anthracycline protein kinase C (PKC)-activating agents developed… 
2001
2001
Drug sequestration in cytoplasmic organelles does not contribute to the diminished sensitivity of anthracyclines in multidrug resistant K562 cells.
Cells that acquire multidrug resistance (MDR) are characterized by a decreased accumulation of a variety of drugs. In addition… 
Highly Cited
2000
Highly Cited
2000
Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
Highly Cited
1997
Highly Cited
1997
Electrostatic and non-electrostatic contributions to the binding free energies of anthracycline antibiotics to DNA.
The knowledge about molecular factors driving simple ligand-DNA interactions is still limited. The aim of the present study was… 
1994
1994
P‐glycoprotein‐mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells
1994
1994
Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance
In vivo effectiveness of doxorubicin remains restricted due to toxicity and drug resistance. Hydroxyrubicin is a synthetic analog… 
Highly Cited
1993
Highly Cited
1993
Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity
Hydroxyrubicin, a synthetic doxorubicin analog in which the basic amino group at C-3' is replaced by a hydroxyl group, was used… 
1984
1984
Synthesis and antitumor activity of 3'-deamino-3'-hydroxydoxorubicin. A facile procedure for the preparation of doxorubicin analogs.
Two successful routes have been developed for preparation of 3'-deamino-3'-hydroxydoxorubicin (11), based on protection of the 14… 
1984
1984
3'-Deamino-4'-epi-3'-hydroxy-daunorubicin and -doxorubicin. Synthesis and antitumor activity.
3'-Deamino-4'-epi-3'-hydroxy-daunorubicin (11) and -doxorubicin (14) have been synthesized. In the in vivo murine P-388… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License